Q4 2023 · 13F-HR
Flagship Pioneering, LLCholdings as filed
Filed 2024-02-14 · accession 0000950123-24-002510
$1.33B
Reported value
7
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | Moderna Inc | $961.3M | 72.5% | 9,666,038 | Common | SHARED |
| 799566104 | SANA | Sana Biotechnology Inc | $102.0M | 7.70% | 25,001,856 | Common | SHARED |
| 68217N105 | — | Omega Therapeutics Inc | $88.0M | 6.64% | 29,225,579 | Common | SHARED |
| 344174107 | FHTX | Foghorn Therapeutics Inc | $81.7M | 6.17% | 12,674,120 | Common | SHARED |
| 24823R105 | DNLI | Denali Therapeutics Inc | $49.8M | 3.76% | 2,319,968 | Common | SHARED |
| 81750R102 | MCRB1EUR | Seres Therapeutics Inc | $32.4M | 2.45% | 23,117,045 | Common | SHARED |
| 87184Q206 | SYRS | Syros Pharmaceuticals Inc | $10.1M | 0.76% | 1,293,848 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.